Outcome prediction for 3 risk groups

Estimated 3-year progression-free survival (PFS) and overall survival (OS) with 95% confidence intervals (CI) in a pooled analysis of 653 CLL patients treated with ibrutinib [1-2].

Reference:

1. Ahn IE, Tian X, Ipe D, et al. Prediction of Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. Journal of Clinical Oncology. 2021, 39 (6), 576-585.

2. The Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health.